Rituximab 100mg Injection

Rituximab 100mg Injection is a precision-engineered chimeric monoclonal antibody that has become a cornerstone in the biological treatment of lymphoid malignancies and severe autoimmune diseases. This medication targets the CD20 antigen, a protein found exclusively on the surface of pre-B and mature B-lymphocytes. By binding to this specific antigen, Rituximab 100mg Injection marks the B-cells for destruction through three powerful mechanisms: Complement-Dependent Cytotoxicity (CDC), Antibody-Dependent Cellular Cytotoxicity (ADCC), and the direct induction of apoptosis (programmed cell death). This targeted depletion of B-cells interrupts the pathological cycle of cancer cell proliferation in lymphomas and leukemias, and halts the production of autoantibodies in autoimmune conditions. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for achieving disease remission, offering a versatile dosing option that ensures precise treatment tailored to the individual patient’s body surface area.

The 100mg vial strength is specifically designed to offer dosing flexibility and precision. It allows pharmacists and oncologists to minimize wastage when compounding specific doses calculated by Body Surface Area (BSA) (e.g., combining a 500mg vial with a 100mg vial to achieve a 600mg dose). This vial size is also particularly useful for pediatric protocols or for specific autoimmune regimens where lower total doses may be required compared to aggressive lymphoma treatments.

Indications / Uses of Rituximab 100mg Injection

Rituximab 100mg Injection is commonly prescribed for the specialized management of the following conditions:

• Non-Hodgkin’s Lymphoma (NHL): It is indicated for the treatment of relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL, and as a first-line treatment for Diffuse Large B-Cell Lymphoma (DLBCL) in combination with chemotherapy.
• Chronic Lymphocytic Leukemia (CLL): The medication is used in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with CD20-positive CLL, helping to extend progression-free survival.
• Rheumatoid Arthritis (RA): Rituximab 100mg Injection is indicated for adults with moderately to severely active RA who have had an inadequate response to TNF antagonist therapies, effectively reducing joint damage and physical disability.
• Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA): It is FDA-approved for the treatment of these rare autoimmune vasculitis conditions, providing an effective alternative to cyclophosphamide.
• Pemphigus Vulgaris (PV): It serves as a critical first-line therapy for moderate to severe pemphigus vulgaris, promoting the healing of skin blisters and reducing the need for high-dose steroids.

Key Features

• Precision Dosing Format: The 100mg/10mL vial allows for accurate fine-tuning of calculated doses, reducing drug waste and ensuring cost-effective pharmacy management.
• Targeted B-Cell Depletion: The primary feature of Rituximab 100mg Injection is its specificity for the CD20 antigen, sparing stem cells and allowing for eventual immune reconstitution.
• Triple-Mechanism Action: It utilizes the body’s own immune system (complement and effector cells) alongside direct signaling to eliminate malignant cells.
• Chemosensitizing Effect: When used with chemotherapy, it disrupts tumor cell defenses, making the cancer more susceptible to cytotoxic drugs.
• Broad Therapeutic Utility: It effectively bridges oncology and rheumatology, treating both cancers and autoimmune disorders with a single biological agent.

Storage for Rituximab 100mg Injection

To preserve the structural integrity and ultimate potency of the protein, Rituximab 100mg Injection must be stored under refrigeration at a temperature between 2°C and 8°C (36°F to 46°F). It is vital to keep the vials in their original outer carton to protect them from light, as exposure can degrade the antibody. Do not freeze or shake the vials; shaking can cause foaming and protein denaturation. Once diluted for infusion, the solution is physically stable for 24 hours at 2°C to 8°C and an additional 24 hours at room temperature, but immediate use is recommended to maintain microbiological safety. Store the medication in a secure, professional medical refrigerator strictly out of the reach of children.

Important Note on Rituximab 100mg Injection

The administration of Rituximab 100mg Injection requires comprehensive safety protocols. Infusion-Related Reactions (IRR) are the most common adverse event, characterized by fever, chills, rigors, hypotension, and dyspnea. These reactions can be severe or fatal. Pre-medication with acetaminophen, an antihistamine, and often a corticosteroid is mandatory 30 to 60 minutes before each infusion to mitigate these risks.

A critical Boxed Warning exists for Hepatitis B Virus (HBV) Reactivation. The drug can cause the reactivation of dormant Hepatitis B, leading to fulminant hepatitis and hepatic failure. All patients must be screened for HBV (HBsAg and anti-HBc) before initiation.

Progressive Multifocal Leukoencephalopathy (PML), a rare and often fatal brain infection, has been reported; monitor patients for any new neurological signs like confusion, dizziness, or loss of balance. Severe Mucocutaneous Reactions (e.g., Stevens-Johnson Syndrome) and renal toxicity from Tumor Lysis Syndrome are also potential risks. Because Rituximab 100mg Injection suppresses the immune system, live virus vaccines are contraindicated during treatment and until B-cell recovery. By strictly following these professional guidelines and premedication strategies, healthcare providers can safely utilize Rituximab 100mg Injection to provide life-saving outcomes.